DiaMedica Reports Q4 2025 Earnings with Updated Financials and Clinical Progress
DiaMedica (DMAC) reported financial results for the fourth quarter of 2026, showing increased cash reserves due to share sales. The company also provided updates on its DM199 preeclampsia program, including clinical progress and regulatory advancements in Canada.
Tickers: $DMAC
Topics: clinical_trials pharma_financials research_development